MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$51,240K
Net Income
-$230,378K
Net Profit Margin
-449.61%
EPS
-$0.22
Unit: Thousand (K) dollars
Revenue Breakdown
Product
Product And Service Other
Revenue Breakdown
Gross profit
Cost of sales
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
51,240
44,206
38,285
32,061
Cost of sales
298
238
382
177
Research and development-Nonrelated Party
57,690
64,770
60,808
48,661
Research and development-Related Party
3,126
3,219
3,049
2,571
Selling, general and administrative-Nonrelated Party
50,626
44,461
37,833
35,508
Selling, general and administrative-Related Party
1,197
1,309
896
774
Impairment of intangible assets
-
-
0
-
Total operating costs and expenses
112,937
113,997
102,968
87,691
Loss from operations
-61,697
-69,791
-64,683
-55,630
Interest and investment income, net
3,155
2,314
2,298
2,067
Change in fair value of related-party convertible note-Related Party
-95,964
-236,625
-191
-1,169
Change in fair value of warrant liabilities
44,190
295,413
-30,743
-14,905
Interest expense related to revenue interest liability
17,192
13,871
12,299
12,302
Interest expense-Related Party
14,032
14,559
14,843
15,256
Change in fair value of derivative liabilities
-692
1,108
-1,400
289
Interest expense-Nonrelated Party
20
34
50
26
Loss on equity method investment
-
-
0
-
Other income (expense), net
242
-5,917
-1,668
-187
Total other expense, net
-168,693
-562,997
2,590
-11,679
Loss before income taxes and noncontrolling interest
-230,390
-632,788
-62,093
-67,309
Income tax expense
0
9
-135
-35
Net loss
-230,390
-632,797
-61,958
-67,274
Net loss attributable to noncontrolling interests, net of tax
-12
-15
-14
-21
Net loss attributable to immunitybio common stockholders
-230,378
-632,782
-61,944
-67,253
Basic EPS
-0.22
-0.62
-0.062
-0.07
Diluted EPS
-0.22
-0.62
-0.062
-0.07
Basic Average Shares
1,050,070,000
1,026,874,000
991,473,000
946,601,000
Diluted Average Shares
1,050,070,000
1,026,874,000
991,473,000
946,601,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Net loss
attributable to immunitybio...
-$230,378K
(-148.91%↓ Y/Y)
Net loss
attributable to...
-$12K
(36.84%↑ Y/Y)
Net loss
-$230,390K
(-148.87%↓ Y/Y)
Loss before income
taxes and...
-$230,390K
(-149.60%↓ Y/Y)
Product
$50,672K
(91.79%↑ Y/Y)
Product And Service
Other
$568K
(14100.00%↑ Y/Y)
Total other expense,
net
-$168,693K
(-702.54%↓ Y/Y)
Loss from operations
-$61,697K
(13.45%↑ Y/Y)
Interest and investment
income, net
$3,155K
(173.63%↑ Y/Y)
Total revenue
$51,240K
(93.91%↑ Y/Y)
Other income
(expense), net
$242K
(187.05%↑ Y/Y)
Change in fair value of
related-party convertible...
-$95,964K
(-8309.07%↓ Y/Y)
Change in fair value of
warrant liabilities
$44,190K
(1236.28%↑ Y/Y)
Interest expense related
to revenue...
$17,192K
(28.25%↑ Y/Y)
Interest
expense-Related Party
$14,032K
(-9.32%↓ Y/Y)
Total operating costs
and expenses
$112,937K
(15.58%↑ Y/Y)
Change in fair value of
derivative liabilities
-$692K
(-135.84%↓ Y/Y)
Interest
expense-Nonrelated Party
$20K
(300.00%↑ Y/Y)
Research and
development-Nonrelated Party
$57,690K
(10.03%↑ Y/Y)
Selling, general and
administrative-Nonrelated Party
$50,626K
(20.94%↑ Y/Y)
Research and
development-Related Party
$3,126K
(11.40%↑ Y/Y)
Selling, general and
administrative-Related Party
$1,197K
(151.47%↑ Y/Y)
Cost of sales
$298K
(119.12%↑ Y/Y)
Buy us a coffee
ImmunityBio-logo-inverted-svg-svg
ImmunityBio, Inc. (IBRX)
ImmunityBio-logo-inverted-svg-svg
ImmunityBio, Inc. (IBRX)
Show more